Dipen Sangurdekar

Dipen Sangurdekar, VP of Data Sciences at KSQ Therapeutics, dives into the innovative fusion of data science with gene and cell therapy. He shares his transition from engineering to oncology, highlighting the integration of computational techniques in therapeutic design. The discussion covers advancements in CRISPR technology, emphasizing its potential for personalized medicine and the challenges of patient variability. Dipen stresses the importance of collaboration between data scientists and biologists to refine therapeutic models, underscoring the critical role of data in drug development.